TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05205083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant novel coronavirus vaccine (CHO cells)
Description: At 3-9 months after the immunization with 2 doses of inactivated vaccine (BBIBP-CorV), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
Study: NCT05758532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-Mumps-Rubella vaccine (MMR)
Description: 0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles-Mumps-Rubella vaccine (MMR)
Description: 0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-Mumps-Rubella vaccine (MMR)
Description: 0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-Mumps-Rubella vaccine (MMR)
Description: 0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh
Study: NCT05107648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gardner GOALS
Description: 12 lesson curriculum focusing on healthy eating, increased physical activity and decreased screen time
Study: NCT05722561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Motivational Counseling
Description: At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, 6), 15\~20 minutes each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth Motivational Counseling
Description: At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, 6), 15\~20 minutes each.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Product
Description: Combination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).
Description: Participants are to use the electronic cigarette freely as replacement for smoking combustible cigarettes.
Study: NCT04797806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.

Intervention type: DRUG
Group type: OTHER
Intervention: Icotinib
Description: Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
Study: NCT05614648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine Micropellets
Description: 0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tuohy epidural needle
Description: 18-gauge Tuohy epidural needle using a custom-built injector

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tuohy epidural needle
Description: 18-gauge Tuohy epidural needle using a custom-built injector
Study: NCT05116306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with hyaluronic acid gel
Study: NCT05922241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Costophrenic assisted cough
Description: Therapist places the hands on the costophrenic angles of the patient's rib cage. During the patient's inspiration, the therapist applies a series of three repeated quick-stretch contractions down and in to encourage maximal inspiration. At the end of expiration, the therapist applies a quick stretch down and in on the patient's lower chest to facilitate a stronger diaphragmatic and intercostal muscle contraction. While instructing the patient to cough, the therapist applies strong pressure through the hands in toward the central tendon of the patient's diaphragm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior chest compression
Description: The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process
Study: NCT05273541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coronavirus vaccination
Description: Patients in this trial need to accept a prime-boost vaccination against SARS-CoV-2 after 6 to 8 months of the first vaccination
Study: NCT06507527

Intervention type: OTHER
Intervention: Collection of variables
Description: This is an observational study, so no interventions that are not routine clinical practice are performed. It is only about collecting information on variables that are already collected in normal clinical practice.
Study: NCT06181370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGMB-447
Description: AGMB-447 inhaled drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo inhaled drug
Study: NCT05079477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to sugar-sweetened beverage warning labels
Description: Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to calorie information
Description: Calories for all beverages and foods

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to calorie information
Description: Calories for all beverages and foods
Study: NCT06256991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer 8400 MG [Veltassa]
Description: Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
Study: NCT05375864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorption test
Description: Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.
Study: NCT05406609

Intervention type: OTHER
Intervention: Cost
Description: Costs of operating room, drugs and equipments which are used by anesthesia

Intervention type: OTHER
Intervention: Cost
Description: Costs of operating room, drugs and equipments which are used by anesthesia

Intervention type: OTHER
Intervention: Time
Description: Time of using operating room

Intervention type: OTHER
Intervention: Time
Description: Time of using operating room
Study: NCT05116306

Intervention type: DRUG
Group type: OTHER
Intervention: Propylene glycol
Description: lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with Propylene glycol gel
Study: NCT05220813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: local infiltration by lidocaine in the surgical site

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: 44patients will receive bupivacaine in ilioinguinal \& iliohypogastric nerve blocks
Study: NCT06030739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
Study: NCT06118008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20094 5mg
Description: Administrated by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20094 10mg
Description: Administrated by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20094 15mg
Description: Administrated by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20094 20mg
Description: Administrated by subcutaneous injection
Study: NCT04912089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGENT
Description: COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGENT
Description: COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
Study: NCT04199052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LinkPositively
Description: LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
Study: NCT06357585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web based education
Description: Web-based training will be provided to the parents in the experimental group regarding care practices for children diagnosed with leukemia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inactive group
Description: Parents in the control group will continue to receive routine care and treatment.
Study: NCT06231680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity
Study: NCT04758923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy
Description: Under General anaesthesia cholecystectomy and CBD exploration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy
Description: Under General anaesthesia cholecystectomy and CBD exploration
Study: NCT05010447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Coach App
Description: The avatar-guided app aims to deepen the user's understanding of Acceptance and Commitment Therapy (ACT) and promote application of ACT skills in every-day-life. Event-Sampling-Methodology (ESM) is used to capture the user's progress as it unfolds.
Study: NCT05611502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TMS will be administered in a pattern that is either excitatory or inhibitory.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: TMS will be administered in a pattern that is either excitatory or inhibitory.
Study: NCT06520007

Intervention type: DRUG
Intervention: Doxycyclin
Description: The drug has been prescribed, as in normal clinical practice, with the National Healthcare System. Patients have been fully informed about interactions, toxicity and posology schedule.

Intervention type: DRUG
Intervention: Doxycyclin
Description: The drug has been prescribed, as in normal clinical practice, with the National Healthcare System. Patients have been fully informed about interactions, toxicity and posology schedule.
Study: NCT05476523

Intervention type: OTHER
Intervention: NeuraLight
Description: NeuraLight is an investigational software-based platform used for measuring eye movements in response to visual stimuli and captured using a simple webcam
Study: NCT06194344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized imagery
Description: Study personnel will assist participants to create scripts that foster relaxation and safety. Objects, places, and/or scenarios that foster participant relaxation, sense of safety, and/or positive emotions will be identified. Participants will write or type the generated scenario using highly detailed elements (e.g., including visual, olfactory, auditory, tactile, and gustatory sensations, as applicable) associated with the imagery. Study personnel will assist with recording the imagery scripts; audio files will be recorded using an audio recording application. The imagery scripts will be played at night via Bluetooth earbuds connected to the Muse app and script recording while laying down to sleep. The imagery rehearsal prompts will play for approximately 15 minutes, based on 10-20-minute recommendations across imagery rehearsal therapy (IRT) studies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will wear the earbuds, with use of Muse S headband to collect outcome data without the individualized imagery scripts.
Study: NCT06203587

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347
Description: The dose of \[68Ga\]Ga-NOTA-WWH347 or \[18F\]F-H3RESCA-WWH347, calculated from the patient's body weight, was 1.8-3.7 MBq \[0.05-0.1 mCi\]/kg, and was administered as an intravenous push, with a single dose given once.
Study: NCT04662372

Intervention type: OTHER
Intervention: Description
Description: description of the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.
Study: NCT05933590

Intervention type: DIAGNOSTIC_TEST
Intervention: Cervical Joint Repositioning Error Assessment
Description: The cervical joint repositioning error assessment is a non-invasive diagnostic test used to measure the ability of an individual to accurately reproduce a specific head position in different orientations (flexion, neutral position, 50% range of motion of left rotation, and 50% range of motion of right rotation). Participants in both the chronic migraine group and the control group will undergo this assessment using a digital inclinometer. The primary outcome of this study is the difference between the initial and repositioned cervical joint angles, measured in degrees.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cervical Joint Repositioning Error Assessment
Description: The cervical joint repositioning error assessment is a non-invasive diagnostic test used to measure the ability of an individual to accurately reproduce a specific head position in different orientations (flexion, neutral position, 50% range of motion of left rotation, and 50% range of motion of right rotation). Participants in both the chronic migraine group and the control group will undergo this assessment using a digital inclinometer. The primary outcome of this study is the difference between the initial and repositioned cervical joint angles, measured in degrees.
Study: NCT06231680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide 50mg
Description: Thalidomide 50mg，po qd；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide 100mg
Description: Thalidomide 100mg，po qd；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide 100mg
Description: Thalidomide 100mg，po qd；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide 200mg
Description: Thalidomide 200mg，po qd；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Platinum-based chemotherapy:~1. Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;~2. Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD;~3. Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Platinum-based chemotherapy:~1. Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;~2. Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD;~3. Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.
Study: NCT06470633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab 1200mg iv q3w

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasoun（HIFU）
Description: HIFU treatment at lesion site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2 iv q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90mg/m2 iv q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 iv q3w
Study: NCT04772651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary coaching
Description: dietary coaching
Study: NCT05178706

Intervention type: OTHER
Intervention: upper extremity rehabilitation program
Description: Patients with FSHD who have undergone and have not undergone surgery will be given activity training by the same physiotherapist after they agree to participate in the study. Both groups will be given the same exercises, the same number of repetitions and the same frequency. A two-phase exercise protocol will be established and progression will be performed after 4 weeks. The exercises will be based on the upper extremity and will include various types of exercises and the primary affected November muscles in the upper extremity. It is planned that the exercises will be accompanied by a physiotherapist 2 days a week, with a total of 16 sessions for 8 weeks. It is planned that there will be a total of 8-10 exercises in 10 repetitions in the exercise program. The total length of the exercise session will be 30 minutes. It is planned that the same physiotherapist will be one-on-one with the patient from the beginning to the end of the exercises.

Intervention type: OTHER
Intervention: upper extremity rehabilitation program
Description: Patients with FSHD who have undergone and have not undergone surgery will be given activity training by the same physiotherapist after they agree to participate in the study. Both groups will be given the same exercises, the same number of repetitions and the same frequency. A two-phase exercise protocol will be established and progression will be performed after 4 weeks. The exercises will be based on the upper extremity and will include various types of exercises and the primary affected November muscles in the upper extremity. It is planned that the exercises will be accompanied by a physiotherapist 2 days a week, with a total of 16 sessions for 8 weeks. It is planned that there will be a total of 8-10 exercises in 10 repetitions in the exercise program. The total length of the exercise session will be 30 minutes. It is planned that the same physiotherapist will be one-on-one with the patient from the beginning to the end of the exercises.

Intervention type: DIAGNOSTIC_TEST
Intervention: Results of assessment
Description: The total follow-up period of participants included in intervention programs will be 8 weeks. Evaluations will be evaluated by physiotherapist before and at the end of treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Results of assessment
Description: The total follow-up period of participants included in intervention programs will be 8 weeks. Evaluations will be evaluated by physiotherapist before and at the end of treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Results of assessment
Description: The total follow-up period of participants included in intervention programs will be 8 weeks. Evaluations will be evaluated by physiotherapist before and at the end of treatment.